Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mesalamine delivery systems: do they really make much difference?

Altamash I Qureshi1, Russell D Cohen

  • 1Department of Internal Medicine, Wayne State University, Detroit Medical Center, USA.

Advanced Drug Delivery Reviews
|November 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Upadacitinib on Cardiovascular Events and Lipid Values in Older Inflammatory Bowel Disease Patients with Baseline Cardiovascular Risk.

The American journal of gastroenterology·2026
Same author

Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease.

Digestive diseases and sciences·2026
Same author

Colonic Tissue Expression of MAdCAM-1 Is Not Predictive of Vedolizumab Responsiveness in Inflammatory Bowel Disease.

Clinical and translational science·2025
Same author

A positive <i>Clostridioides difficile</i> test does not impact outcomes in hospitalized patients with acute severe ulcerative colitis.

Therapeutic advances in gastroenterology·2025
Same author

Safety and Efficacy of Upadacitinib in Patients with Inflammatory Bowel Disease After Liver Transplantation: A Case Series.

Digestive diseases and sciences·2025
Same author

Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same journal

Silicone oil in protein drug products and its implications for formulation stability.

Advanced drug delivery reviews·2026
Same journal

Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD).

Advanced drug delivery reviews·2026
Same journal

Lysosome-targeting degrader delivery system: from formulation design to biomedical applications.

Advanced drug delivery reviews·2026
Same journal

Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities.

Advanced drug delivery reviews·2026
Same journal

Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapies.

Advanced drug delivery reviews·2026
Same journal

Light-controlled CRISPR-dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications.

Advanced drug delivery reviews·2026
See all related articles

New aminosalicylates target inflammatory bowel disease (IBD) by delivering mesalamine directly to the bowel. Various delivery systems exist, requiring careful patient selection for optimal therapeutic outcomes.

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Drug Delivery Systems

Background:

  • Sulfasalazine was a first-line therapy for inflammatory bowel disease (IBD).
  • Development of "designer" aminosalicylates aimed to improve mesalamine delivery and reduce sulfa-moiety side effects.
  • Aminosalicylates target the inflamed bowel, with varying release mechanisms and absorption profiles.

Purpose of the Study:

  • To review the different delivery systems for aminosalicylates used in IBD treatment.
  • To discuss the pharmacology and clinical relevance of differing absorption rates.
  • To highlight the importance of understanding individual drug release systems, patient states, and intolerances.

Main Methods:

  • Review of aminosalicylate formulations and their release mechanisms.

Related Experiment Videos

  • Comparison of drug delivery strategies targeting the small and large bowel.
  • Discussion of pharmacokinetic differences and clinical implications.

    • Main Results:

    • Aminosalicylates utilize azo-bond, pH-dependent, or moisture-release systems for mesalamine delivery.
    • Direct application via enema or suppository is effective for distal colitis.
    • Pharmacology and absorption rates vary, but clinical significance is debated.

    Conclusions:

    • Understanding the diverse release systems and patient-specific factors is crucial for effective aminosalicylate therapy in IBD.
    • Tailoring treatment based on delivery mechanisms, patient conditions (fed/fasting), and individual tolerances optimizes patient outcomes.
    • Further research may clarify the clinical importance of pharmacokinetic differences among aminosalicylates.